Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (81-90 of 352) with videos related to

Pageof 36
Sort By:
World Journal of Gastroenterology|September 30, 2006
Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's diseaseGottfried Novacek, Wolfgang Miehsler, Julia Palkovits, et al.
The American Journal of Gastroenterology|September 6, 2022
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY StudyNeeraj Narula, Emily C L Wong, John K Marshall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 28, 2025
Week 12 Reduction in MM-SES-CD is Predictive of Delayed Response to Upadacitinib in Crohn's diseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Digestive Diseases and Sciences|February 19, 2026
Impact of Comorbid Psoriasis on the Efficacy of Ustekinumab and Mirikizumab in Inflammatory Bowel Disease: A Post-hoc Analysis of UNITI, SEAVUE, and LUCENTEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Inflammatory Bowel Diseases|February 26, 2011
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARERobert Löfberg, Edouard V Louis, Walter Reinisch, et al.
Scandinavian Journal of Gastroenterology|April 23, 2015
A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel diseaseWalter Reinisch, Istvan Altorjay, Ferenc Zsigmond, et al.
Inflammatory Bowel Diseases|July 22, 2015
Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa StudyAlexander Eser, Jean-Frederic Colombel, Paul Rutgeerts, et al.
Inflammatory Bowel Diseases|December 30, 2021
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs AdalimumabParambir S Dulai, Emily C L Wong, Walter Reinisch, et al.
The American Journal of Gastroenterology|October 24, 2003
Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatmentAlexander Teml, Verena Kratzer, Barbara Schneider, et al.
Advances in Therapy|November 10, 2021
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab BiosimilarWalter Reinisch, Stanley Cohen, Monica Ramchandani, et al.
Pageof 36

Showing results (81-90 of 352) with videos related to

Sort By:
Pageof 36
World Journal of Gastroenterology|September 30, 2006
Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's diseaseGottfried Novacek, Wolfgang Miehsler, Julia Palkovits, et al.
The American Journal of Gastroenterology|September 6, 2022
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY StudyNeeraj Narula, Emily C L Wong, John K Marshall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 28, 2025
Week 12 Reduction in MM-SES-CD is Predictive of Delayed Response to Upadacitinib in Crohn's diseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Digestive Diseases and Sciences|February 19, 2026
Impact of Comorbid Psoriasis on the Efficacy of Ustekinumab and Mirikizumab in Inflammatory Bowel Disease: A Post-hoc Analysis of UNITI, SEAVUE, and LUCENTEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Inflammatory Bowel Diseases|February 26, 2011
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARERobert Löfberg, Edouard V Louis, Walter Reinisch, et al.
Scandinavian Journal of Gastroenterology|April 23, 2015
A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel diseaseWalter Reinisch, Istvan Altorjay, Ferenc Zsigmond, et al.
Inflammatory Bowel Diseases|July 22, 2015
Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa StudyAlexander Eser, Jean-Frederic Colombel, Paul Rutgeerts, et al.
Inflammatory Bowel Diseases|December 30, 2021
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs AdalimumabParambir S Dulai, Emily C L Wong, Walter Reinisch, et al.
The American Journal of Gastroenterology|October 24, 2003
Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatmentAlexander Teml, Verena Kratzer, Barbara Schneider, et al.
Advances in Therapy|November 10, 2021
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab BiosimilarWalter Reinisch, Stanley Cohen, Monica Ramchandani, et al.
Pageof 36